Nerixia (nerindronic acid) / Lee's Pharm, Abiogen, Grunenthal, Takeda - LARVOL DELTA

Evidence-Based Therapeutic Methods for Reflex Sympathetic Dystrophy: A Systematic Review. (PubMed, Cureus) - "Neridronate appeared to be the most promising pharmaceutical strategy in the research reviewed. However, the heterogeneity in treatment methods, outcome measures, and sample sizes restricts the generalizability of the results. More large-scale, high-quality randomized controlled studies are needed to provide uniform treatment guidelines and maximize clinical outcomes in patients with CRPS."

Journal • Review • Musculoskeletal Pain • Pain

Acute Orbital Inflammation following Neridronate Therapy: A Case Report. (PubMed, Case Rep Ophthalmol) - "While most reported cases involve agents such as zoledronate or alendronate, reports associated with neridronate remain exceedingly rare...Following the initiation of high-dose oral prednisone (1 mg/kg/day), the patient exhibited rapid clinical improvement within 48 h and near-complete radiologic resolution by 15 days. This case underscores the importance of recognizing neridronate-associated orbital inflammation as a potential adverse reaction, even following intramuscular injection. Despite its severe presentation, the condition typically demonstrates a rapid and favorable response to systemic corticosteroid therapy."

Journal • Dermatology • Inflammation • Musculoskeletal Pain • Ocular Inflammation • Ophthalmology • Pain • Scleritis • CRP

CRPS-RISE Outcomes Registry (clinicaltrials.gov) - P=N/A | N=270 | Not yet recruiting | Sponsor: Ambros Therapeutics, Inc.

New trial • Musculoskeletal Pain • Pain

Neridronate in Pediatric Osteogenesis Imperfecta: Real-World Multicenter Evidence on Bone Density and Fracture Reduction (ESPE 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Genetic Disorders • Musculoskeletal Diseases • Orthopedics • Pediatrics

Long-term effects of Neridronate on growth pattern and fracture burden in pediatric patients with Osteogenesis Imperfecta: a multicenter retrospective study (ESPE 2026) - No abstract available

Retrospective data • Genetic Disorders • Musculoskeletal Diseases • Orthopedics • Pediatrics

Neridronate in Pediatric Osteogenesis Imperfecta: Real-World Multicenter Evidence on Bone Density and Fracture Reduction (ESPE 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Genetic Disorders • Musculoskeletal Diseases • Orthopedics • Pediatrics

MRI Distribution of Foot Bone Marrow Edema of Presumed Algodystrophic/BMES-Like Origin: A Small Retrospective Case Series with 3-Month Clinical Follow-Up. (PubMed, J Clin Med) - "However, the uncontrolled design, small sample size, concomitant vitamin D supplementation, adjunctive physiotherapy or magnetotherapy in many patients, and self-limiting nature of BMES-like conditions prevent attribution of these changes to neridronate or to any single treatment component. The apparent relationship between multi-compartment edema and greater pain severity was based on only two patients and should be regarded only as a weak exploratory observation."

Journal • Retrospective data • Immunology • Pain

Efficacy of Anti-Osteoporotic Drugs and Vitamin D/calcium Supplementation in NMD: A Systematic Review (ICNMD 2026) - "Among anti-osteoporotic agents, zoledronate was most commonly employed (37.9%), followed by pamidronate (20.6%) and alendronate (17.2%)...Risedronate and neridronate did not demonstrate consistent benefits. Limited evidence suggested denosumab effectively improved BMD in small patient samples, whereas teriparatide maintained stable BMD values. This analysis highlights a lack of data on bone health management in NMD, particularly regarding specific age groups and rarer subtypes... This analysis highlights a lack of data on bone health management in NMD, particularly regarding specific age groups and rarer subtypes. These gaps emphasize the necessity of a targeted, evidence-based approach to prevent and treat bone loss. Early therapeutic interventions, guided by the biological rationale of anti-osteoporotic agents, represent a critical strategy to optimize bone health in NMD, in order to preserve functional capacity, skeletal integrity, and quality of life."

Clinical • Review • CNS Disorders • Duchenne Muscular Dystrophy • Genetic Disorders • Movement Disorders • Muscular Atrophy • Muscular Dystrophy • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rare Diseases

Efficacy and Safety of Neridronate for the Treatment of Fragility Fractures in Duchenne Muscular Dystrophy (ICNMD 2026) - "<span style='font-family:"Times New Roman",serif; color:black;"

Clinical • Duchenne Muscular Dystrophy • Genetic Disorders • Muscular Dystrophy • Musculoskeletal Diseases • Orthopedics

Effectiveness and safety of Neridronate in Chronic Nonbacterial Osteomyelitis: insight from the CAMELOT registry (EULAR 2026) - "The most frequently used BP in CNO is pamidronate, whose effectiveness has been documented in few studies...During follow-up, 7 out of 14 patients (54%) who initially received NER alone required subsequent treatment with DMARDs: methotrexate (MTX, n=2), etanercept (n=1), and adalimumab (n=4)...Conclusions The present study presents NER as a safe and effective therapeutic tool for CNO, highlighting the importance of accurate patient selection, favoring those with recent onset, spine involvement and a low number of peripheral lesions. In the near future, it would be advisable to validate outcome parameters for CNO activity and conduct a comparative study to improve the management of these patients."

Clinical • Inflammation • Musculoskeletal Diseases • Orthopedics • CRP

Open Pyeloplasty in Infants and Small Children: An Operative Guide (AUA 2026) - "AHDP remains the gold-standard surgical treatment of UPJ obstruction. Given MIS advances and OP declining volume; training/practice paradigms that optimize experience and skill maintenance, including intra-departmental specialization and inter-departmental collaboration should be considered to maximize exposure of trainees and staff to OP."

Clinical • Nephrology

Effectiveness and safety of neridronate in chronic nonbacterial osteomyelitis: insight from the CAMELOT registry. (PubMed, Ther Adv Musculoskelet Dis) - "Bisphosphonates (BPs) are used to treat of CNO with most clinical experience involving pamidronate. Neridronate appears to be a safe and effective option for CNO, particularly in patients with recent-onset disease, spinal involvement, and fewer peripheral lesions. Early initiation may be associated with higher rates of complete response, though further studies are needed to confirm these findings."

Journal • CNS Disorders • Inflammation • Musculoskeletal Diseases • Orthopedics

Safety of intravenous neridronate in pediatric patients: insights from the monocentric retrospective NAPOLEON cohort. (PubMed, Ther Adv Musculoskelet Dis) - "Premedication with prednisone does not seem to be effective in the prevention of APR. NER appears safe across different pediatric conditions, with predictable first-infusion reactions. The role of vitamin D and premedication in children candidate to NER infusion should be further confirmed in larger cohorts."

Journal • Retrospective data • Endocrine Disorders • Genetic Disorders • Orthopedics • Pediatrics • Rheumatology

Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE) (clinicaltrials.gov) - P3 | N=270 | Recruiting | Sponsor: Ambros Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Musculoskeletal Pain • Pain

Managing Public-Private Partnerships for Health Diagnostics: Challenges and Strategies. (PubMed, Health Policy Plan) - "We used an extensive document review and 72 recent key informant interviews (KIIs), building on 63 KIIs previously conducted to analyze the African Health Diagnostics Platform (AHDP) project in-depth...In particular, we propose investment in training government and technical assistance providers in health PPPs; development of repositories of guidance documents to support health PPPs; employment of systems-thinking based planning approaches that illuminate connections across the health system; more sophisticated approaches to stakeholder management; and investment in research that supports modelling of different PPP arrangements and how their progression is influenced by local contextual factors. While evidence on the impact of health PPPs remains scarce, moves towards increased healthcare corporatization in the context of dwindling aid underscores the urgency of building experience and evidence on PPPs in healthcare and other social sectors."

Journal • Licensing / partnership

Acute Phase Reaction After First Neridronate Infusion in Children with Osteogenesis Imperfecta: An Analysis Based on Questionnaire Data from 65 Patients. (PubMed, Paediatr Drugs) - "Fever and skeletal pain are common yet self-limiting side effects after first neridronate infusion in children with OI. Adequate pain medication and caregiver education are important to improve treatment adherence and patient comfort during initiation of bisphosphonate therapy."

Journal • Genetic Disorders • Pain • Pediatrics

Clodronate and Neridronate: cornerstones of Osteometabolic therapy. (PubMed, Clin Ter) - "Among the tested drugs, bisphosphonate, particularly Neridronate and Clodronate, have shown promising results. Despite differences in dosage and therapeutic regimens, these compounds have demonstrated the ability to reduce pain symptoms and structural alterations."

Journal • Review • Immunology • Musculoskeletal Pain • Osteoarthritis • Osteoporosis • Pain • Rheumatology

Previously Unreported TMEM38B Variant in Osteogenesis Imperfecta Type XIV: A Case Report and Systematic Review of the Literature. (PubMed, Int J Mol Sci) - "The patient exhibited multiple skeletal deformities and showed a moderate response to bisphosphonate therapy (neridronate)...While bisphosphonates provide some clinical benefit, persistent fractures underscore the need for long-term management and innovative therapies. This case report and systematic review enhance understanding of OI type XIV and underscore the clinical importance of TMEM38B variants in bone fragility disorders."

Journal • Review • Genetic Disorders • Musculoskeletal Diseases • Orthopedics • COL1A1 • COL1A2

Bone Marrow Edema and Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia. (PubMed, Diagnostics (Basel)) - "Case 1 developed unilateral then bilateral knee BME, temporally associated first with dasatinib and subsequently with imatinib; symptoms improved after TKI interruption, bisphosphonate therapy, and supportive measures, and did not recur after switching to bosutinib. Case 2 presented with proximal femoral BME during long-term imatinib; imatinib was stopped, intravenous neridronate administered, and bosutinib initiated with clinical recovery and later near-complete radiological resolution...Prompt recognition with targeted MRI and a multidisciplinary, stepwise approach that includes temporary TKI adjustment, bone-directed therapy, and consideration of PDGFR-sparing alternatives can mitigate morbidity while maintaining disease control. Prospective studies are needed to define incidence, risk factors, optimal prevention, and management strategies."

Journal • Chronic Myeloid Leukemia • Hematological Malignancies • Immunology • Leukemia • Oncology • KIT • PDGFRB

Repurposing osteoporosis medications for other diseases: a narrative review by the European Calcified Tissue Society (ECTS). (PubMed, Bone) - "Repurposing osteoporosis medications represents a cost-effective, timely strategy to expand treatment options across diverse clinical indications. While promising outcomes have been demonstrated-particularly in rare diseases-rigorous, indication-specific clinical trials are essential to confirm efficacy, safety, and long-term outcomes. The accumulated pharmacologic and clinical experience with these agents offers a strong foundation for their continued exploration beyond osteoporosis."

Journal • Review • Endocrine Disorders • Hypoparathyroidism • Immunology • Langerhans Cell Histiocytosis • Musculoskeletal Pain • Osteoarthritis • Osteoporosis • Pain • Rare Diseases • Rheumatoid Arthritis • Rheumatology

Efficacy and Safety of Bisphosphonates for Complex Regional Pain Syndrome : A Systematic Review and Meta-analysis. (PubMed, Ann Intern Med) - "Eleven trials (754 participants; CRPS type I, 97%), evaluating alendronate (n = 2), clodronate (n = 1), neridronate (n = 5), pamidronate (n = 1), and zoledronate (n = 2), were included. None. (PROSPERO: CRD42024559783)."

Journal • Retrospective data • Review • Musculoskeletal Pain • Pain

Transient Osteoporosis of the Hip: Clinical and Radiological Outcomes After Combined Pharmacologic and Biophysical Therapy. (PubMed, J Clin Med) - "The aim of this study was to evaluate clinical outcomes following treatment with Neridronate, Clodronic Acid, Cholecalciferol, and pulsed electromagnetic field therapy (PEMF). Early diagnosis and timely intervention are essential to progression to osteonecrosis. A combined therapeutic approach using bisphosphonates, vitamin D, and PEMF appears effective in reducing symptoms, promoting bone healing, and ensuring good patient compliance."

Journal • Immunology • Osteoporosis • Pain • Rheumatology

A precision medicine approach to identifying patients with Complex Regional Pain Syndrome Type 1 who may benefit from neridronate (ASRA-FALL 2025) - P3 | "• Overall, 206 participants across 3 trials had CRPS-1 at baseline (Table 1). • Trial KF7013-02 Red and/or warm affected limb subgroup (scored as yes/no): • The analysis included participants with CRPS-1 and available Week 12 pain intensity scores with (n=12) and without (n=19) physical exam findings of affected limb redness and/or warmth prior to receiving study treatment. • Treatment with neridronate in participants with a red and/or warm affected limb at baseline showed a greater LS mean difference12week in average pain intensity of -2.11 (95% CI: -3.99, -0.23; nominal p=0.03; Table 2) compared to those without these inflammatory signs at baseline (-1.14; 95% CI: -1.92, -0.36; nominal p=0.004; Table 2)."

Clinical • Inflammation • Musculoskeletal Pain • Pain

Beyond Averages: Informing Clinical Decision Making in the Pharmacologic Treatment of CRPS-1 using Bayesian Network Meta-Analysis (ASRA-FALL 2025) - "Across 17 trials, a total of 375 subjects were randomized to active treatment arms, and 379 to placebo. The evidence network was a placebo-anchored star (Figure 1), with edge thickness proportional to the number of trials per comparison. Treatments included: Neridronate: n=160 Ketamine: n=79 Alendronate: n=59 Pamidronate: n=48 Gabapentin: n=46 Corticosteroids: n=41 Mannitol: n=41 IVIG: n=13 Scavengers / Magnesium Sulfate: n=257 Ranked posterior probabilities of achieving a ≥20 mm VAS pain reduction, alongside average placebo-adjusted effects and 95% credible intervals, are summarized in Table 2."

Late-breaking abstract • Retrospective data • Musculoskeletal Pain

Pivotal phase 3 trial of neridronate in Complex Regional Pain Syndrome Type 1: CRPS-RISE study design and methodology (ASRA-FALL 2025) - P3 | "For example: • Analgesics, such as acetaminophen, nonsteroidal anti-inflammatory drugs, opioids ≤ 45 morphine equivalents/day, and neuropathic therapies (e.g., gabapentinoids) • Physical therapy, occupational therapy, rehabilitation modalities, psychological or psychiatric modalities Rescue Treatment • Rescue medications are permitted to treat pain and include: • 1st line: Acetaminophen, with a total daily dose ≤ 4 grams/day • 2nd line: For moderate to severe pain (e.g., > 4 on 0-10 scale) that persist 30 min after acetaminophen was taken as rescue, oxycodone 5 mg immediate release may be taken (up to 4 times/day) Prophylaxis of Acute Phase Reaction • Short-term use of IV bisphosphonates, as in the case of this trial, is generally well-tolerated, with the most common adverse event expected to be acute phase reaction...• Given the progressive nature of CRPS and the different subtypes, it is important to consider a precision medicine approach that targets the right..."

P3 data • CNS Disorders • Musculoskeletal Pain • Pain • Psychiatry • Rare Diseases • Sleep Disorder